CITIUS PHARMACEUTICALS INC

CTXRNASDAQ

🏆 #4847 by market capEarnings Dec 21 · PostUS Equity

$0.56▲ $0.00 (+0.09%)

Market closed · at close

🔔

Track CTXR

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 0.1%

7d▼ 5.5%

14d▼ 5.6%

30d▼ 4.4%

ytd▼ 27.5%

1y▼ 54.9%

🏦Market Cap

$15M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $0.55 – $0.56
52-Week Range: $0.47 – $2.19
Volume: $3.17B
Avg Volume: $2.22B
Shares Outstanding: 27.4M
Next Earnings: Oct 31, 2026

Fundamentals Snapshot

Annual Revenue: $1M
Last Q Revenue: $301,989
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-2.13
Dividend Yield: —
Dilution (1yr): +85.5%

Why Investors Own CTXR

✓High-growth profile — revenue up +41.8% YoY with expanding US Equity exposure.
✓Healthy economics — 40% gross margin and 5% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CITIUS PHARMACEUTICALS INC

CTXR

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$39M▼ −8.3% YoY

Free Cash Flow

−$27M▼ −5.8% YoY

Shares Outstanding

21.5M▲ +85.5% YoY

Net Cash

$6M▲ +$5M YoY

StockOtter · stockotter.space

About CITIUS PHARMACEUTICALS INC

Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

🦦